ArticleJournal of neuro-oncology2025
Tumor and immune cell distribution in the tumor core and outer part of glioblastoma, IDH wildtype.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Comment on "The microenvironment of glioblastoma: in pursuit of universal multimodal immunotherapy".Acta neurologica Belgica · 2026Article
- Immune Subtypes and Survival in Patients with Primary Glioma.medRxiv : the preprint server for health sciences · 2026Article
- Targeting regulatory T cells in glioblastoma: from mechanistic insights to novel immunotherapeutic strategies.Frontiers in immunology · 2026Review
- Arterial spin-labeling-based exchange time mapping for differentiation of high-grade glioma and brain metastases.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGlioblastoma, IDH-wildtype is the most frequent and malignant primary brain tumor in adults. Tumor cells infiltrate the brain parenchyma, preventing complete resection and causing progression. Immune therapies have limited effect, but little is known about the frequency and type of immune cells in the outer part of glioblastoma, IDH-wildtype, where tumor cells start to infiltrate the brain (transition zone) and diffusely infiltrate the brain parenchyma (tumor periphery). We aimed to quantify the type and distribution of immune cells in glioblastomas, IDH-wildtype covering these areas.
methodsWe established a cohort of 54 glioblastomas, IDH-wildtype containing tissue from the tumor core, transition zone, and periphery. Patients were included if most tumor cells were positive in immunohistochemical staining for P53. Tissue sections were subject to multiplex immunohistochemistry and stained with P53 (tumor), FOXP3 (regulatory T cells), CD8 (cytotoxic T cells), and IBA1 (microglia/macrophages). A software-based classifier was trained to count the cells.
resultsThe densities of CD8+, FOXP3+, and IBA1+ cells were significantly higher in the core than in the periphery and in the transition zone than in the periphery. However, the CD8+, FOXP3+, and IBA1+ cell/tumor cell ratio increased from the core to the transition zone, and the CD8+ and IBA1+ cell/tumor cell ratio increased again to the periphery. The core had the highest FOXP3+/CD8+ ratio, as well as the highest fraction of tumor cells with IBA1+ cells, CD8+ cells, and FOXP3+ cells in proximity.
conclusionThis study highlights spatial differences in the immune microenvironment with potential implications for future immune-therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.